BB's Stock Haven

[Crypto__1]

$VDRM UPDATED DUE DILIGENCE/ RESEARCH 


Christopher Otiko CEO,  DPM

http://www.neurogenx.com/testimonial/christopher-otiko-dpm-ceo-executive-medical-director/

$VDRM This Technology and The Company Are As Real as it gets!


  The Federal Law will validate everything Dr Otiko has stated, leading to a much higher valuation on the stock in my opinion




Two new items in the May 3rd press release Worth Highlighting!



The Company has filed provisional patents on several products, and their pending status has already gone through a screening process by the USPTO.


The Company is moving ahead with its aggressive growth plans and plans to complete its initial production of Viabecline topical antibiotic by the end of Q2."

VDRM VIADERMA NEWS

https://finance.yahoo.com/news/viaderma-inc-vigorously-defend-companys-120000945.html

https://www.otcmarkets.com/stock/VDRM/news


What Is The Buzz Surrounding With Viaderma Inc $VDRM


www.mmjobserver.com/what-is-the-buzz-surrounding-with-viaderma-inc-otcmktsvdrm/28597/


ViaDerma, Inc. (VDRM: OTC Pink Limited) | Attorney Letter with Respect to Current Information

http://www.otcmarkets.com/financialReportViewer?symbol=VDRM&id=171208



The problem Steven Keogh has, is the fact that he has done nothing to "Revive" the abandoned patent in a reasonable time and failed to respond to the US PATENT TRADE OFFICE! He has ZERO rights to any technology related to the patent / intellectual property referred to in the lawsuit. 

https://www.uspto.gov/web/offices/pac/mpep/s711.html ;

Therefore, this patent application is deemed "dead". First to file does not apply on abandoned patent applications. 

http://patentassociate.com/patentblog/2016/09/21/reviving-abandoned-patents/ ;


Case will be dismissed in my opinion!


VDRM will have the right to countersue based on defamation, financial damages and false allegations!!!




$VDRM CHECK THIS OUT! SCREEN SHOTS OF THE PATENTS KEOUGH ABANDONED! Case will be dismissed in my opinion based on my conversations with legal professionals, including a patent attorney. 


SCREEN SHOTS DIRECTLY FROM THE US PATENT TRADE OFFICE


https://twitter.com/MOMOSTOCKTRADES/status/856568132646948864


Additional INFORMATION


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=130754240



VDRM / CHART is A Beauty!


http://stockcharts.com/c-sc/sc?s=VDRM&p=D&b=5&g=0&i=t12669425044&r=1491246424508


$VDRMhttps://www.barchart.com/stocks/quotes/VDRM ;


Per INVESTOR RELATIONS "News due out very soon. I inquired about FDA approval for the cream / spray and was advised it should be 6 to 8 weeks from April 5th, putting us at a target date sometime during the last 2 weeks in May! 


Product will begin rolling out in 45 to 60 days. "


Based on the previous press releases:

Expecting the following:

Drugs in pipeline - Updates

Product Rollouts

Lawsuit update

Company response to lawsuit

Company clarification to lawsuit details

Additional intellectual property/ Patent Filings

Initial Product Manufacturing and Launch

FDA Product Registration / Approvals

Partnerships

Additional Conferences/ Meetings

Additional Data for Products in pipeline

Etc.







With that being said, there is a SHORTSQUEEZE IMMINENT !


THERE IS HEAVY SHORTING THROUGH CITADEL,  MARKET MAKER CDEL.  


HERE'S A REPORT DIRECTLY FROM FINRA.


http://otcshortreport.com/?index=VDRM&action=view


$VDRM UPDATED SUPPLY VS DEMAND /



SHORT SELLERS ARE CLEARLY LOSING CONTROL AND THIS IS ON THE VERGE OF EXPLODING HIGHER.  FACTS ARE BELOW!

#SHORTSQUEEZE IMMINENT


ALL READ THE FOLLOWING! 


<<<<SEE NEW SHORT INTEREST FIGURES BELOW>>>


The SHORT Reports are Reported Directly From Finra! 


There's ZERO BS.  IT'S FACTS, and extremely telling!


Anyone thinking about selling INTO this RALLY, really needs to think twice!

There's a reason why the PERCENTAGE of Volume SOLD SHORT per day has increased so dramatically!!!

The Short SELLERS got pegged against the wall and are trying to stop the UPWARD MOMENTUM, with there fake walls.

Nobody who's half intelligent would place a large block of shares for sale on the ask.  The blocks are put there to place a psychological block, to deter people from buying.  When you buy into the block, you put FEAR into the short SELLERS and they quickly pullback from there SHORT Attack!

The higher the price goes, the more they lose control!

As the stock climbs, it gains momentum which will lead to a larger climb, creating a short squeeze and "A PANIC BUYING" SITUATION.






 


VDRM Days Volume 7,985,191 NEW RECORD # Shorted for one day = 5/11/17 = 5,035,769 63.06% of Volume  http://otcshortreport.com/?index=VDRM&action=view



VDRM Days Volume 5,462,889 NEW RECORD # Shorted for one day = 5/10/17 = 2,830,328 51.81% of Volume  http://otcshortreport.com/?index=VDRM&action=view



>>>>>>>  VDRM NEW RECORD SHORT Volume for One Day! <<<<<<<<


THIS WILL SQUEEZE HARD!!!



VDRM Days Volume 8,163,772 NEW RECORD # Shorted for one day = 5/9/17 = 6,131,400 75% of Volume  http://otcshortreport.com/?index=VDRM&action=view


VDRM Volume 10,880,426 # of Shares Shorted 5/8/17 =7,123,809 65.47% of THE Days Total Volume 


http://otcshortreport.com/?index=VDRM&action=view


$VDRM MAY 5Th 2017 Volume 4,849,891 # of Shares Shorted WAS 1,987,459 Representing 40.98% of May 5ths Total Volume

http://otcshortreport.com/?index=VDRM&action=view


MAY 4th 2017


FACT! NEW RECORD SHORT INTEREST FOR 1 DAY! $VDRM Volume 5,397,797 # of Shares Shorted Today 3,154,634 Representing 58.44% of May 4ths Total Volume

http://otcshortreport.com/?index=VDRM&action=view


$VDRM May 3rd 2017 Volume 9,834,653 # of Shares Shorted of which 5,636,599 Representing 57.31% of Total Volume for the day was shares SOLD Short


http://otcshortreport.com/?index=VDRM&action=view


Now let's put this into perspective, shall we!! 

This stock is being artificially held down.  The volume is at record lows for four straight business days.  The majority of the shares being sold, are from short sellers.  


There is practically no more shares available at this level.

So what you see taking place, is trading from one short seller to another. 

They artificially dropped the share price down by selling back and forth between there accounts, using the same shares. 

THE minute any volume comes in to buy, that is not a short seller, the stock instantaneously rises on the bid and ask at the same time. 

Most shareholders are holding, as 90% of the weak hands have sold. 

So there continuously shaking the tree by creating artificial volume at a deflated stock price,  hoping to create fear.  (Based on the volume, they have already lost!)

But what actually has taken place is, the entire floats been locked up by stronger hands, creating added pressure on short SELLERS.  (Now they are forced to try and figure out ways to create fear, hence misleading posts, rumors, confusion etc.)

This is a coiled spring and will explode higher in a matter of days just like it has done over and over, during the past 4 months.  

Be strong and don't fall for these games!  Place a bid in , good til canceled and take away the remainder of the shares from short SELLERS. . 


http://otcshortreport.com/?index=VDRM&action=view


There is a HIGH LIKELYHOOD OF a SHORT SQUEEZE   < You can't short millions of SHARES everyday, forever!!!  


The next major news will ignite a massive rally in my opinion. 





Note, if you buy at the ask, the large blocks that appear to be on the sell side, quickly vanish. 

If you buy at the ask, short SELLERS quickly hit the bid with a small amount to make it appear like there's selling pressure.  

This one's ready!  Do not fall for the short SELLERS tactics.   


Recommend reading the following information:


http://counterfeitingstock.com/CS2.0/CS16ConfessionsOfAPaidStockBasher.html


_____________________________________


Also confirmed with Management that there will be ZERO DILUTION from today until September 2017.  CONFIRMED !


_______________________________________



PER IR " In the last month there were 10 million shares issued as a result of a convertible note. There are no more issuance is expected until another note comes due beginning in either September or October and it will be staggered for a couple months. So no more issuance of shares until the fall" 


"To date not one single Insider has sold any shares"


"Dr Otiko owns over 40 million shares and has not SOLD any shares" directly from IR


INVESTOR RELATIONS

RICHARD INZA 1-954-251-0616 or 1-310-734-6111 


[e-mail]

____________________________________








$VDRM DUE DILIGENCE 



The CEO of VDRM was involved with Phillips on inventing a transdermal delivery system that changes drugs into an ointment for better absorption . 


Steven Keogh was the patent attorney several years back.  The guys trying to say he had rights to the patent.  Which is freakin ridiculous.   He's known to be a corrupt attorney who trys to steal intellectual property. So he recently filed a suit against VDRM over the patent.  It's a Frivolous suit in my view.  Hence the reason the stock dipped.

Steven Keogh is a piece of doodoo patent attorney , trying to extort money from company.

Read this article  



http://patrickpretty.com/2010/03/26/inetglobal-accuses-former-ceo-of-extortion-bid-says-company-is-solvent-accuses-government-of-leaking-search-warrant-affidavit-to-press/

Keoughs patent expired!


It was abandoned which means that it was never issued because he abandoned it before seeing through the entire process.

Once it's abandoned its fair game anybody can claim it.

But either way the patent that we have is different than the abandoned patent. 


We're not even fighting over the same technology as far as I am aware.


Dr Christopher Otiko made changes and improved upon the original technology. He greatly advanced it and filed provisional patents for the new technology. 


I did verify the original patent (Referenced by Stephen Keough) was abandoned via us patent trade office.


This is FACTUAL, NOT SPECULATION. 


HERE IT IS, DIRECTLY FROM THE US PATENT ORGANIZATIONS WEBSITE!

13/729,776 TOPICAL DRUG DELIVERY SYSTEM WITH DUAL CARRIERS 
Status: Abandoned -- Failure to Respond to an Office Action 
Status Date: 11-16-2015 
First Named Inventor: D. Howard Phillips , Millerton, OK 
First Named Applicant: PHARMACLINE, LLC , Minneapolis, MN 


Patent info from DR Otiko took 20 mins for response...


The original patent filed by Steve Keough was abandoned. Keough the patent attorney for Dr. Phillips who invented the technology with my assistance. I was responsible for 90% of the data that led to the patent, HOWEVER Keough put himself on as an inventor, which wasnt true. The patent was abandoned because Keough and Dr. Phillips had a falling out. I filed a provisional patent to protect the IP. 
Hope this helps clarify things. 


Dr. Chris Ayo Otiko, 
President & CEO 
ViaDerma, Inc 
Corporate Headquarters 
4640 Admiralty Way Suite 500, Marina Del Rey, CA 90292 
Phone: [phone] 
Fax: [phone]
viadermalicensing.com/ 




People are missing this KEY section. 

Directly from the Annual Report


"Furthermore,
the predecessor transdermal technology, which is the subject of dispute by Mr. Keough, is not even
currently used by the Company and any protections related to its provisional patents are believed to have
expired. All new products being developed and sold by the Company are based on a newer transdermal
technology created directly by the Company or its management team. "



RECENT THIRD PARTY DUE DILIGENCE


$VDRM Here's Something Viaderma Inc $VDRM Shareholders Should See

By Chris Sandburg / in Biotech, Momentum & Growth, Momentum Stocks, Stocks / on Wednesday, 10 May 2017 10:58 AM / 0

 

https://www.insiderfinancial.com/viaderma-inc-otcmktsvdrm-a-bit-of-due-diligence-on-the-patent-claims/122577/

Viaderma Inc (OTCMKTS:VDRM) took a bit of a hit recently based on the surfacing of some litigation related to the delivery method associated with its lead asset. Over the last few days, however, the company has recovered much of the lost ground, trading up to the tune of around 20% on the Monday open at current prices (midsession on Wednesday) and up close to 10% for the day so far.

With the potential for an FDA green light for its lead registration asset just around the corner, and the company fresh off the back of what was reported as being a successful conference presentation by its CEO relating to the lead target indication – diabetic foot ulcer therapy – it looks as though we could be in for some strength. The litigation dampens sentiment somewhat, however, right now, but a little bit of digging reveals that sentiment need not be impeded by what’s going on.

Here is why.

By way of a bit of background, Viaderma has developed a topical antibacterial formulation of an already FDA registered drug, which it has been able to prove in trials has the potential to treat diabetic foot ulcers successfully in more than 90% of applications. This category of condition is crying out for fresh therapy options right now, and a number of companies have failed in their attempts to bring said options to market just recently. We covered this company not long ago, requesting that management put out some degree of insight (by way of a press release or otherwise) as to how the above-mentioned presentation went. To put it bluntly, we felt that the claims made as to the 90% success rate in this indication were too good to be true, and wanted to see how the scientific community responded to said claims.

Shortly after our coverage, we got exactly what were looking for, with this release.

The product is in final testing for manufacturing, and based on the available evidence, should be a shoo-in for a quick transition toward standard of care therapy in this sector. So what’s holding the company back? Well, as mentioned, there is a claim against the technology that underpins the product.

Specifically, one of the guys who worked on a product (a patent lawyer) with the current CEO and the technology’s initial inventor (a scientist) claims to have ownership rights. If this is the case, it’s potentially terminal for the program. However, it doesn’t take too much digging to prove that the claim is essentially baseless.

Head over to this site.

Insert the following into the field as an application number: 13/729776.

This is the application number for the patent that the guy we’re talking about is trying to challenge – his name is Steven Keough and he’s listed as an inventor on the patent, along with D. Howard Phillips.

Check the status of the patent:

” Abandoned — Failure to Respond to an Office Action”

So first of all, the patent isn’t even a patent – it’s an application.

More important that that, however, it has been abandoned. When a patent application gets abandoned it’s as if nothing has ever been filed. Even if an individual is listed as an inventor on the application, his or her rights to any return based on future commercial application of the technology covered by the initial application are non-existent.

This is all based on a bit of research in a murky area – we aren’t patent lawyers and we don’t work at the USPTO. We may be misinterpreting something (although we’re pretty certain we aren’t), so we’re going to say that it’s important for anyone thinking about acting on our coverage to do a bit of due diligence before doing so.

All said, however, this just looks like a bit of opportunism from Keough.

If that’s the case, then, our bull thesis remains firm, and our attention returns to the science (and the therapeutic application) as near term value inputs.

We will be updating our subscribers as soon as we know more. For the latest updates on VDRM, sign up below!

Sign up for next microcap runner ahead of the crowd.






I bought.  If the lawsuit gets dismissed it will skyrocket in my opinion as the lawsuit basically VALIDATES there's significant value on the patent not currently priced in!


Good luck to all!